Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Resolve Therapeutics (Seattle, WA), a preclinical-stage biotechnology company focused on the development of lupus treatments, closed a $5.8M Series B financing. Participants include New Science Ventures, Easton Capital and WRF Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive […]

Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

NanoString Technologies (Seattle, WA) a commercial-stage cell assay device company focused on direct digital detection for gene expression analysis, closed $20M Series D financing. Participants include General Electric, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

RF Surgical Systems (Bellevue, WA) a commercial-stage medical device company focused on the prevention and detection of retained surgical items, closed a $12M Series B financing. Participants include Split Rock Partners and Menlo Ventures.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Adaptive TCR (Seattle, WA) a commercial-stage provider of online solutions for large scale immune system profiling, closed a $5.8M Series B financing, bringing the total round to $10.3M. Participants were not identified. The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science […]

Stratos Genomics (Seattle, WA) a development-stage device company focused on a ultra-low-cost nucleic acid sequencing method for whole genome analysis and molecular diagnostics, closed a $2.1M Series A financing, bringing the total round to $6.1M. Participants have included Fisk Ventures. The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are […]

Resolve Therapeutics (Seattle, WA) a preclinical-stage biopharmaceutical focused on the treatment of lupus,closed a $2M Series A financing. Participants include New Science Ventures and Easton Capital.

Oncofactor (Seattle, WA) a development stage biopharmaceutical company focused on oncology, closed a $2.1M Series A financing. Participants include Accelerator, OVP Venture Partners, Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners and WRF Capital.

Mirador Biomedical (Seattle, WA) a development-stage medical device company focused on single use pressure transducers for use with central venous catheters, closed a $1.5M Series B financing. Participants include WRF Capital and Summit Capital.

PhysioSonics (Seattle, WA) a development-stage device company focused on ultrasound imaging to monitor blood flow in the brain, closed a $3.6M Series B financing. Participants include Medtronic.

Acylin Therapeutics (Seattle, WA) a development-stage biopharma company focused on inhibiting histone acetyltransferase in cancer, metabolic disease, and neurodegeneration indications, closed a $4.4M Series F financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD and Washington Research Foundation Capital.

Immune Design (Seattle, WA) a development-stage therapeutic vaccine company focused on oncology and infectious disease, closed a $32M Series B financing. Participants include ProQuest Investments, Column Group, Versant Ventures and Alta Partners.

« Previous Entries  Next Page »

to top of page...